Joint strategy sets direction for EMA and EU medicines regulatory agencies to 2025

Joint strategy sets direction for EMA and EU medicines regulatory agencies to 2025

The pandemic crisis has shown many problems linked to medicines and the mechanism ahead of their regulation. For this reason, EMA (European Medicines Agency) and HMA (Head of Medicines Agencies) came together to look ahead and develop an overarching European medicines agencies network strategy which sets precise targets until 2025 to shape the future role of medicines regulation nationally and at the EU level, and enhance the partnership approaches necessary to ensure that Europe is proactively positioned to deal with similar emergencies.

Six priorities have been identified which must be fulfilled by 2025 in this organisational and planning framework drawn up by EMA and HMA:

  • availability and accessibility of medicines;
  • data analytics, digital tools and digital transformation;
  • innovation;
  • antimicrobial resistance and other emerging health threats;
  • supply chain challenges;
  • sustainability of the network and operational excellence.

Further information about the strategy settled by EMA and HMA can be found on EMA website.

2021-01-28T11:37:01+00:00 27/01/2021|Categories: News|